lispro

Generic Name: lispro

Clinical Trials

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: HDV-Lispro
Drug: Lispro

First Posted Date: 2024-02-02

Last Posted Date: 2024-12-10

Lead Sponsor: Diasome Pharmaceuticlas, Inc.

Target Recruit Count: 230

Registration Number: NCT06238778

Locations: 🇺🇸
Diabetes Research Center, Tustin, California, United States
🇺🇸
East Coast Institute for Research, Canton, Georgia, United States
🇺🇸
Physicians Research Associates, LLC, Lawrenceville, Georgia, United States

and more 21 locations

Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)

Not Applicable

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Lispro

First Posted Date: 2022-12-21

Last Posted Date: 2023-10-31

Lead Sponsor: Manchester University NHS Foundation Trust

Target Recruit Count: 26

Registration Number: NCT05660941

Locations: 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Sitagliptin 100mg
Drug: Glargine
Drug: Lispro

First Posted Date: 2022-10-13

Last Posted Date: 2023-09-26

Lead Sponsor: Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social

Target Recruit Count: 76

Registration Number: NCT05579119

Locations: 🇲🇽
División de Investigación en Salud, Hospital de Especialidades, Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico

Remission Through Early Monitored Insulin Therapy - Duration Month

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Glargine
Drug: Lispro
Device: Dexcom G6

First Posted Date: 2018-09-13

Last Posted Date: 2021-10-12

Lead Sponsor: Sandra Sobel

Target Recruit Count: 10

Registration Number: NCT03670641

Locations: 🇺🇸
UPMC Falk Diabetes Clinic, Pittsburgh, Pennsylvania, United States

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: Exenatide
Drug: Lispro

First Posted Date: 2016-02-24

Last Posted Date: 2020-03-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 92

Registration Number: NCT02690883

A Study of Lispro Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lispro

First Posted Date: 2014-11-18

Last Posted Date: 2015-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT02293551

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

Insulin Bolus Required for High Fat Foods in Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Lispro

First Posted Date: 2014-09-25

Last Posted Date: 2017-04-26

Lead Sponsor: Joslin Diabetes Center

Target Recruit Count: 10

Registration Number: NCT02248454

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Hyperglycemia
Hospitalization

Interventions: Drug: glargine
Drug: lispro
Drug: Sitagliptin

First Posted Date: 2011-06-22

Last Posted Date: 2018-12-07

Lead Sponsor: Emory University

Target Recruit Count: 90

Registration Number: NCT01378117

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lispro

First Posted Date: 2010-07-12

Last Posted Date: 2014-04-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT01159938

Locations: 🇫🇮
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Viaject 7
Drug: LISPRO

First Posted Date: 2010-04-27

Last Posted Date: 2015-08-03

Lead Sponsor: Biodel

Target Recruit Count: 20

Registration Number: NCT01110746

Locations: 🇺🇸
Oregon Health and Science University/Legacy Health System, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy